Physician profile
Michael Mcdaniel
NPI 1932327996
$3,781.49
in general payments reported to CMS, 2019-2025
36 companies · $599 in 2025
The $599 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $767 · 2022: $867 · 2023: $644 · 2024: $906 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.05 | 2021-2025 | |
| Novo Nordisk INC | $813.40 | 2021-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $268.51 | 2021-2024 | |
| Lilly USA, LLC | $135.34 | 2021-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $134.50 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $124.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.88 | 2021-2024 | Jardiance |
| Supernus Pharmaceuticals, INC. | $85.24 | 2024 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.61 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $84.21 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $58.07 | 2021-2022 | |
| Alkermes, INC. | $57.68 | 2025 | Lybalvi, Aristada |
| Glaxosmithkline, LLC. | $57.48 | 2021-2022 | |
| Astellas Pharma US INC | $50.81 | 2021-2023 | Veozah |
| Exact Sciences Corporation | $44.84 | 2023-2024 | Cologuard Collection Kit |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.